A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two doses of nebulised budesonide delivered by the VR475 Inhalation System, with an open-label comparison to conventionally nebulised budesonide, in patients with uncontrolled asthma despite treatment with high dose inhaled corticosteroid and at least a second controller (GINA Step 4) and those receiving oral corticosteroid (GINA Step 5)
Latest Information Update: 29 Apr 2019
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Vectura
- 26 Mar 2019 Primary endpoint (The annualised rate of clinically significant exacerbations during the Treatment Period.) has not been met.
- 26 Nov 2018 Results published in the Vectura Media Release
- 30 Oct 2018 Status changed from active, no longer recruiting to completed.